Wegovy is approved for use in adults with a BMI of 30 or higher, although there are certain medical conditions that would make treatment inadvisable.
This BMI cut off is lowered to 27 for those who also have at least one weight-related condition. Some examples include high blood pressure, type 2 diabetes, high cholesterol, sleep apnoea, gastro-oesophageal reflux, weight-related depression or joint pain. We will ask you about this as part of the onboarding process.
People of certain ethnic origins (Asian, Black Afro-Caribbean, Arabs) are more prone to developing type 2 diabetes and cardiovascular complications of obesity at lower BMIs than Caucasians and this may be taken into account when deciding if you are suitable for treatment.
Complete our free, online medical questionnaire to determine whether you are suitable for the SemaPen programme.